KDM4D Drugs: A Promising New Class of Treatments (G55693)

Target Name: KDM4D

NCBI ID: G55693

KDM4D

KDM4D Drugs: A Promising New Class of Treatments

KDM4D (Ketone-Dependent Macrolide Inhibitors) are a novel class of drugs that are currently being developed for the treatment of various diseases, including diabetes. These drugs work by inhibiting the activity of a protein called NAD+, which is involved in a number of cellular processes that are important for the health and function of the body.

KDM4D drugs have been shown to be highly effective in preclinical studies in treating a wide range of diseases, including diabetes, heart disease, and cancer. They work by inhibiting the activity of NAD+, which is a critical coenzyme that is involved in many important cellular processes. This includes the regulation of metabolism, the production of energy, and the response to stress.

In addition to their potential use in treating diseases, KDM4D drugs have also been shown to have a number of potential applications in research. For example, they have been used to treat a variety of cellular diseases, including cancer, and have been shown to have a positive impact on the survival rates of cancer patients.

KDM4D drugs have also been shown to have a positive impact on the health and function of the liver, which is an important organ that is involved in the production of bile and the detoxification of harmful substances in the body. This has led to the development of KDM4D drugs as potential treatments for a variety of liver diseases, including cirrhosis.

Overall, KDM4D drugs have the potential to be a valuable tool in the treatment of a wide range of diseases. While further research is needed to fully understand their potential and to develop safe and effective treatments, KDM4D drugs have shown promise in preclinical studies and have the potential to be a valuable addition to the treatment options available for a variety of diseases.

Protein Name: Lysine Demethylase 4D

Functions: Histone demethylase that specifically demethylates 'Lys-9' of histone H3, thereby playing a central role in histone code. Does not demethylate histone H3 'Lys-4', H3 'Lys-27', H3 'Lys-36' nor H4 'Lys-20'. Demethylates both di- and trimethylated H3 'Lys-9' residue, while it has no activity on monomethylated residues. Demethylation of Lys residue generates formaldehyde and succinate

The "KDM4D Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about KDM4D comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets